Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells.
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.
Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
MicroRNA signatures differentiate melanoma subtypes.
Phosphoproteomic screen identifies potential therapeutic targets in melanoma.
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.